Loading clinical trials...

A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus

A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus

NCT07073170•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Are native Chinese
•Have type 2 diabetes for at least 6 months
•Have been treated with diet and exercise, with or without a stable dose of metformin for at least 3 months
•Have hemoglobin A1c (HbA1c) of at least 7% and no greater than 10%
•Have a body mass index (BMI) of at least 20 milligrams per square meter (kg/m2) and no greater than 40 kg/m2
•Have had a stable body weight for the 3 months prior to screening
•Women must not be of childbearing potential

Exclusion Criteria

•Have type 1 diabetes or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization
•Have had an episode of severe hypoglycemia within 6 months or have a history of hypoglycemia unawareness
•Have a clinically significant gastric emptying abnormality
•Have or have a history of pancreatitis
•Have signs and symptoms of liver disease, with the exception of non-alcoholic fatty liver disease
•Have a personal or family history of multiple endocrine neoplasia syndrome type 2 or medullary thyroid carcinoma
•Have an uncontrolled endocrine abnormality
•Have an abnormal blood pressure or pulse rate
•Have a 12-lead electrocardiogram (ECG) abnormality
•Have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data

Locations (3)

Peking University People's Hospital

Beijing, China

West China Hospital of Sichuan University

Chengdu, China

Peking University First Hospital

Dongcheng District, China

Key Dates

Start Date

July 25, 2025

Primary Completion Date

January 27, 2026

Completion Date

January 27, 2026

Last Updated

March 3, 2026

Enrollment

ACTUAL participants

Conditions

Type 2 Diabetes

Interventions

LY3549492

DRUG

Placebo

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGPHASE2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484

Type 2 DiabetesCortisol Excess

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

SGLT2i, Pioglitazone, and Ketone Production in T2D

Closed-loop in Adults With Type 2 Diabetes